Drug intelligence / Profile preview

BA-5

Development stage: Preclinical
Modality: Small Molecules
Administration: Intraperitoneal Injection

Overview

BA-5 is a novel barbituric acid derivative investigated for the treatment of hepatocellular carcinoma (HCC) and sorafenib-resistant HCC. It exerts its antitumor effects by significantly inhibiting cell viability in a dose- and time-dependent manner. Its mechanism of action involves decreasing the phosphorylation of AKT and p70s6k, activating apoptosis through increased cleavage of PARP and caspase-7, and inhibiting cell migration by reducing Vimentin protein expression. BA-5 has shown synergistic effects when combined with low doses of sorafenib or regorafenib in HCC and sorafenib-resistant HCC cells, respectively.

Other names: barbituric acid derivative BA-5

Targets

AKT (RAC-alpha serine/threonine-protein kinase)

Beyond the preview

Go deeper on BA-5.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BA-5.

Explore the full profile